High Purity 99% Retatrutide Peptide CAS 2381089-83-2 | Weight Loss & Metabolic Support 40mg

--What is Retatrutide ？

Retatrutide is a triple glucagon, GIP, and receptor agonist. Retatrutide showed glucose control and weight loss in patients with type 2 diabetes mellitus (T2DM).Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor .

Retatrutide can be used for the research of obesity.Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides.

Retatrutide: The "Triple-Target" Breakthrough Technology in Weight Loss. You may have heard of Semaglutide and Tirzepatide, but the evolution of weight loss medicine never ceases. As a new-generation metabolic powerhouse, Retatrutide—distinguished by its pioneering "triple-target" mechanism—has been hailed by the scientific community as the "gold standard" in the field of weight loss [Lilly's Triple Agonist Retatrutide Demonstrated Significant].

Retatrutide (pronounced Ret-uh-true-tide), once-weekly  medication currently being studied for the treatment of obesity and type 2 diabetes. It is a novel peptide acting as a triple hormone receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By activating all three of these receptors, Retatrutide aims to provide more potent metabolic benefits than medications that target only one or two of these pathways.

Retatrutide is a new-generation, blockbuster "triple-target" metabolic modulator developed by Eli Lilly, hailed by the medical community as the "pinnacle" of weight management and metabolic therapy. Operating through a pioneering "triple-agonist" mechanism, it simultaneously activates three receptors—GLP-1, GIP, and Glucagon. This action not only powerfully suppresses appetite and delays gastric emptying at the source but also actively accelerates caloric expenditure and fat breakdown, achieving a revolutionary leap from merely "controlling intake" to "boosting metabolism." In the recently completed global Phase III TRIUMPH-1 clinical trial, a 12 mg dose of Retatrutide helped patients achieve an average weight reduction of 28.3% (approximately 70 pounds) over 80 weeks, with nearly half of the subjects losing more than 30% of their body weight. These stunning clinical results directly rival the efficacy of bariatric surgery and significantly surpass that of current single- or dual-target therapies available on the market. Beyond its unparalleled weight-loss performance, Retatrutide also demonstrated robust clinical benefits in reversing non-alcoholic fatty liver disease, significantly lowering blood glucose (HbA1c), and comprehensively improving various cardiovascular and metabolic markers. As a trailblazer in the future multi-billion-dollar metabolic market, Retatrutide not only redefines the standard of care for obesity but, backed by safe and groundbreaking scientific data, offers hundreds of millions of patients worldwide—who suffer from overweight conditions, Type 2 diabetes, and fatty liver disease—the ultimate non-invasive solution for scientifically and safely restoring their health without the need for surgery.

--Description 

1.Treatment of depression and anxiety disorders: Retatrutide has been shown to have antidepressant and anxiolytic effects in preclinical studies, suggesting that it could be a promising treatment option for individuals with these conditions.

2.Prevention of neurodegenerative diseases: Retatrutide has neuroprotective properties that may be useful in preventing or slowing the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's.

3.Enhancement of cognitive function: Retatrutide has been shown to improve learning and memory in animal studies, suggesting that it could have potential as a cognitive enhancer in humans.

4.Treatment of chronic pain: Retatrutide has been shown to have analgesic effects in preclinical studies, suggesting that it could be a useful treatment option for individuals with chronic pain conditions.

5.Promotion of wound healing: Retatrutide has been shown to accelerate wound healing in animal studies, suggesting that it could have potential as a therapeutic agent for promoting wound healing in humans. 

1.Retatrutide is often used in the pharmaceutical industry, weight losing, etc.
2.Retatrutide is a kind of peptide product.
3.Retatrutide acetate can inhibited GCGR, GIPR and GLP-1R.
4.Retatrutide acetate is activated by glucagon receptors resulting in significant weight loss and increased energy expenditure.
5.Retatrutide acetate can be used in studies of obesity.



Our company is a modern advanced enterprise specializing in production and exportation of APIs, Pharmaceutical intermediates, plant extracts etc. Our products are widely used in medicine, health care products, cosmetics, nutritional supplements and food additives areas. Those products of both quality and technical content have reached the domestic advanced level. Since its establishment, the company has attached great importance to the team training and technical reform. Our modern production equipment guarantees for a fast and effective production with a superior degree of accuracy throughout the whole production line, everything is done in-house, processing, extraction, packaging and transportation of all links, ensuring maximum quality and efficiency. We are constantly research and development new ingredients and innovative new products, have earned the respect & Admiration from the worldwide customers. After years of continuous development, company has been accumulated rich experience in international trade and customer resources, established a stable customer base and perfect marketing service network. In addition, the company has established long-term technical cooperation with experts and professors from many universities and research institutes in the province.